Pirfenidone NEW

pirfenidone (PFD) is a new pyridinone compound with broad-spectrum antifibrotic effect, which can prevent and reverse fibrosis and scar formation. Marketed by Shionogi in Japan in 2008 and approved by the US Food and Drug Administration, it is the first drug to demonstrate certain efficacy of Chemicalbook in idiopathic pulmonary fibrosis (IPF) through repeated, randomized, placebo-controlled phase III clinical trials. And the drug also has a good effect on renal interstitial fibrosis, liver fibrosis and other fibrosis diseases. It is also widely used in phase II clinical studies of renal disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibroma multiplex, adolescent type I neurofibroma multiplex and plexiform neurofibroma, diabetes with kidney disease, uterine leiomyoma, etc.